Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > More buying

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Dec 20, 2020 9:02am

229 Views

Post# 32148746

RE:More buying

Ditto here. As soon as the new year rolls in, I'm maxing out the tfsa on ATE. The fundementals of this stock are still very impressive.

January will be a very exciting month. My eyes are on the JP morgan event, hopefully Nasdaq uplist prior to.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing